Results 41 to 50 of about 266,823 (339)

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA, BASILI, Stefania, LA TORRE, Giuseppe, LENZI, TOMMASO, PACELLA, Elena, PACELLA, FERNANDA, Pascarella, Antonella   +6 more
core   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco, BOTTONE, Andrea, Domenica Piraino, Carmen, Mollicone, Antonella, PACELLA, Elena, PACELLA, FERNANDA, Romana Parisiella, Francesca, TURCHETTI, PAOLO   +7 more
core   +1 more source

Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. [PDF]

, 2014
To enable new blood vessel growth, endothelial cells (ECs) express neuropilin 1 (NRP1), and NRP1 associates with the receptor tyrosine kinase VEGFR2 after binding the vascular endothelial growth factor A (VEGF) to enhance arteriogenesis.
Alessandro Fantin, Anastasia Lampropoulou, Anissa Chikh, Anselmi, Ballmer-Hofer, Baruzzi, Birukova, Buchdunger, Campochiaro, Carmeliet, Casanovas, Chen, Chen, Chislock, Cho, Choi, Christiana Ruhrberg, Clark, Claudio Raimondi, Colicelli, Connor, Cui, Cujec, Dejana, Druker, Fantin, Fantin, Fantin, Fantin, Foxton, Fukasawa, Gerhardt, Gerhardt, Herzog, Kawamura, Kawasaki, Kim, Kitsukawa, Koch, Lanahan, Lanahan, Laura Denti, Lewis, Lewis, Mamluk, Murga, Nishijima, Pan, Pan, Parsons, Pasapera, Phng, Raimondi, Ren, Robinson, Roig, Rosenfeld, Ruhrberg, Ruhrberg, Saint-Geniez, Salikhova, Shimizu, Shojaei, Smith, Soker, Sottile, Stenzel, Tvorogov, Uemura, Valdembri, Wang, Welti, Yaqoob, Zaidel-Bar, Zhuang   +74 more
core   +4 more sources

Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]

, 2015
Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C, Casarin, A, Indraccolo, Stefano, Nardin, M, Nicoletto, Mo, Pomerri, Fabio, Randon, G, Zulato, E   +7 more
core   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis [PDF]

International Journal of Ophthalmology, 2017
AIM: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus anti-VEGF monotherapy for polypoidal choroidal vasculopathy (PCV).
Long-Hui Han1, Li-Fei Yuan1, Xu Liang2, Xin Jia1, Ming-Lian Zhang1   +4 more
doaj   +1 more source

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma [PDF]

, 2016
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening ...
Andrés Guerrero, Vanessa, García Feijoo, Julián, Herrero Vanrell, Rocío, Konstas, Anastasios Georgios P., Martínez de la Casa, Jose Maria, Morales Fernández, Laura, Pablo Júlvez, Luis, Perucho González, Lucía, Polo Llorens, Vicente, Sáenz Francés, Federico   +9 more
core   +4 more sources

Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future [PDF]

, 2019
Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies.
Corson, Timothy W., Park, Bomina
core   +1 more source

Anti-VEGF Therapies in the Clinic [PDF]

Cold Spring Harbor Perspectives in Medicine, 2012
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest ...
Kellen L, Meadows, Herbert I, Hurwitz
openaire   +2 more sources

Mechanisms of parasite‐mediated disruption of brain vessels

FEBS Letters, EarlyView.
Parasites can affect the blood vessels of the brain, often causing serious neurological problems. This review explains how different parasites interact with and disrupt these vessels, what this means for brain health, and why these processes matter. Understanding these mechanisms may help us develop better ways to prevent or treat brain infections in ...
Leonor Loira, Sílvia Arroz‐Madeira, Cláudio A. Franco, Sara Silva Pereira   +3 more
wiley   +1 more source